Enanta Pharmaceuticals Inc - Asset Resilience Ratio

Latest as of June 2026: 52.58%

Enanta Pharmaceuticals Inc (ENTA) has an Asset Resilience Ratio of 52.58% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ENTA current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$156.09 Million

Cash + Short-term Investments

Total Assets

$296.87 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2011–2025)

This chart shows how Enanta Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Enanta Pharmaceuticals Inc.

Liquid Assets Composition Over Time

This chart breaks down Enanta Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Enanta Pharmaceuticals Inc (ENTA) long-term investment share to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$156.09 Million	52.58%
Total Liquid Assets	$156.09 Million	52.58%

Asset Resilience Insights

Very High Liquidity: Enanta Pharmaceuticals Inc maintains exceptional liquid asset reserves at 52.58% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Enanta Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio

Compare Enanta Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
ALK-Abelló A/S CO:ALK-B	Biotechnology	0.98%
Mirum Pharmaceuticals Inc NASDAQ:MIRM	Biotechnology	6.89%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
BB Biotech AG SW:BION	Biotechnology	92.97%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Beijing Konruns Pharmaceutical Co Ltd SHG:603590	Biotechnology	10.55%

Annual Asset Resilience Ratio for Enanta Pharmaceuticals Inc (2011–2025)

The table below shows the annual Asset Resilience Ratio data for Enanta Pharmaceuticals Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-09-30	55.77%	$156.57 Million	$280.73 Million	-0.24pp
2024-09-30	56.01%	$210.95 Million	$376.65 Million	-5.54pp
2023-09-30	61.55%	$284.52 Million	$462.27 Million	+7.62pp
2022-09-30	53.93%	$205.24 Million	$380.59 Million	+11.56pp
2021-09-30	42.37%	$186.80 Million	$440.86 Million	-18.66pp
2020-09-30	61.03%	$299.52 Million	$490.79 Million	+3.05pp
2019-09-30	57.98%	$284.01 Million	$489.83 Million	-1.12pp
2018-09-30	59.10%	$244.83 Million	$414.23 Million	+10.73pp
2017-09-30	48.37%	$157.99 Million	$326.64 Million	-20.43pp
2016-09-30	68.80%	$193.51 Million	$281.28 Million	+18.60pp
2015-09-30	50.19%	$123.48 Million	$246.01 Million	+11.54pp
2014-09-30	38.65%	$60.06 Million	$155.41 Million	-40.53pp
2013-09-30	79.18%	$92.62 Million	$116.97 Million	+15.44pp
2012-09-30	63.75%	$33.25 Million	$52.16 Million	+0.55pp
2011-09-30	63.20%	$16.49 Million	$26.10 Million	--

pp = percentage points

About Enanta Pharmaceuticals Inc

NASDAQ:ENTA USA Biotechnology

Market Cap

$364.65 Million

Market Cap Rank

#13981 Global

#3349 in USA

Share Price

$12.52

Change (1 day)

-1.42%

52-Week Range

$7.17 - $16.85

All Time High

$126.37